Your browser doesn't support javascript.
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
Poland, Gregory A; Ovsyannikova, Inna G; Kennedy, Richard B.
  • Poland GA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA; Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: poland.gregory@mayo.edu.
  • Ovsyannikova IG; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA; Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Kennedy RB; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA; Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Lancet ; 396(10262): 1595-1606, 2020 11 14.
Article in English | MEDLINE | ID: covidwho-857279
ABSTRACT
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2020 Document Type: Article